Facing drug pricing control and China Trade War, Clovis shares are being clobbered. Nonetheless, the fundamentals are strong.
Rubraca sales for ovarian cancer steadily increase and thereby represent a drug that garners strong sales tractions.
Nonetheless, I'm most interested in Rubraca's development for patients suffering from metastatic castration-resistant prostate cancer with an associated BRCA1/2 mutation.
Management must be willing to submit itself to the disciplines required for sound growth. - Phillip Fisher
In the thick of concerns relating to drug pricing control and China Trade War, Clovis Oncology (NASDAQ:CLVS